E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Body processes [G] - Biological Phenomena [G16] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The study is conducted to assess the relative bioavailability of a reformulated liquid noscapine preparation relative to a marketed liquid reference preparation (Capval Saft) |
|
E.2.2 | Secondary objectives of the trial |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Male / Female • age: at least 18 years old • Body Mass Index 18.5 – 30 kg/m2 • considered healthy on the basis of extensive pre-study screening • willing and capable to confirm written consent to enrolment after ample information has been provided
|
|
E.4 | Principal exclusion criteria |
• subjects with suspicion of hypersensitivity to noscapine or any of the excipients listed in the respective medical product information • subjects with any relevant clinical abnormality (as based on extensive medical history, physical examination, vital signs and 12-lead ECG) • subjects with a history of a major surgical abdominal intervention or of peritonitis within the last year • subjects with psychoses (current or history) • subjects with any clinically relevant laboratory abnormality.
• subjects receiving any medication within 1 week prior to study start or during the study (exceptions possible upon decision of Principal Investigator, e.g. paracetamol single dose for acute pain or topical aciclovir for herpes labialis) • subjects who have taken a drug with a long half-life (> 24 hours) within four weeks before the first trial day (exceptions possible upon decision of Principal Investigator) • subjects who received chronic drug treatment (> 3 days) within eight weeks before the first trial day (exceptions possible upon decision of Principal Investigator) • subjects who participated in a trial with novel investigational medications within the last 8 weeks before the start of the present study • subjects who participated in a trial with a registered compound within the last 4 weeks before the start of the present study • subjects who donated blood or plasma within the last 4 weeks before the start of the present study • subjects who smoke, i.e. subjects who smoked one or more cigarettes during the last six months • subjects who are known or suspected to be (social) drug dependent, incl. those drinking usually more than 30 g alcohol per day • subjects with a history of alcohol or recreational drug addiction • subjects with a history of any severe disease that might interfere with the study objectives (e.g. psychiatric disease, epilepsy) • subjects who are not willing or able to abstain from alcohol, methylxanthine-containing beverages and foods (coffee, tea, cocoa products), and grapefruit, orange, and apple flesh / juice for 72:00 h before first study drug administration until 48 hours after last study drug administration • subjects who adhere to a special diet (e.g. vegetarians) or lifestyle (incl. working at night and extreme physical activities such as competitive sports and weight lifting) that might interfere with the investigation • subjects planning elective hospital treatment within one month after last intake of trial medication • subjects who are known or suspected not to comply with the study directives and/or known or suspected not to be reliable or trustworthy • subjects who are known or suspected not to be capable of understanding and evaluating the information that is given to them as part of the formal information policy (informed consent), in particular regarding the foreseeable risks and discomfort to which they will be exposed. • subjects with anticipated problems of successfully placing an indwelling venous catheter at a forearm • female subjects only: positive results in pregnancy test • female subjects only: lactating women • female subjects only: subjects who do not use or do not agree to use appropriate contraceptive methods during the study as defined in Note for Guidance on Non-Clinical Safety Studies for the Conduct of Human Clinical Trials for Pharmaceuticals (CHMP/ICH/286/95 modification)
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Bioavailability of both preparations compared is within a 0.8 - 1.25 range Main pharmacokinetic parameters of noscapine: AUC0-t(last) Cmax
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
• Additional pharmacokinetic parameters of noscapine: AUC0-∞, residual area, tmax, λz (apparent terminal elimination constant), t½,λz (apparent terminal elimination half-life) • Safety and Tolerability: − Medical history, adverse events and well-being − Laboratory screen (haematology, clinical chemistry and urinalysis) − Physical examination − Vital functions: blood pressure, pulse rate, body temperature − 12-lead ECG
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | Yes |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | Yes |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | Yes |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | Yes |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 0 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | 0 |